PMN Insider Trading Activity and SEC Form 4 Filings
PMN insider trading summary
Over the past 12 months, insiders at ProMIS Neurosciences Inc. (PMN) reported 14 open-market purchases worth $42.8M by 8 insiders and no sales on SEC Form 4. Net insider buying was $42.8M.
Latest PMN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 4, 2026 | Eugene Williams | Director | Buy | $91K (26,500 @ $3.43) |
| Nov 2, 2026 | Neil Cashman | Chief Scientific Officer | Buy | $39K (10,000 @ $3.86) |
| Oct 30, 2026 | Eugene Williams | Director | Buy | $5K (1,316 @ $3.99) |
| Aug 5, 2026 | Johanne Kaplan | Chief Development Officer | Buy | $30K (2,280 @ $13.30) |
| Mar 5, 2026 | Eugene Williams | Director | Buy | $49K (2,000 @ $24.40) |
| Mar 4, 2026 | Eugene Williams | Director | Buy | $48K (2,000 @ $24.00) |
| Mar 3, 2026 | Eugene Williams | Director | Buy | $22K (1,000 @ $21.89) |
| Mar 2, 2026 | Eugene Williams | Director | Buy | $23K (1,000 @ $22.53) |
| Feb 19, 2026 | Johanne Kaplan | Chief Development Officer | Buy | $25K (1,629 @ $15.35) |
| Feb 3, 2026 | Ally Bridge MedAlpha Master Fund L.P. | 10% Owner | Buy | $8.5M (700,741 @ $12.13) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.